Attention Deficit Hyperactivity Disorder Subtypes and Symptom Response in Adults Treated with Lisdexamfetamine Dimesylate

Innovations in Clinical Neuroscience

Brian Scheckner¹  Greg Mattingly¹  Robert Lasser¹  Ben Adeyi¹  Bryan Dirks¹  Thomas Babcock¹  Richard Weisler¹ 

[1] Dr. Mattingly is from Washington University School of Medicine in St. Charles, Missouri; Dr. Weisler is from Duke University Medical Center in Durham, North Carolina, and the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Drs. Dirks, Babcock Scheckner, and Lasser and Mr. Adeyi are from Shire Development LLC, Wayne, Pennsylvania.

关键词: Lisdexamfetamine dimesylate (LDX);    attention-deficit/hyperactivity disorder (ADHD);    adults;    ADHD-RS-IV symptom subtype;    amphetamine;    stimulant;    predominantly inattention;    predominantly hyperactivity/impulsivity;    predominantly combined;    clinical response;   

DOI  :  

学科分类：精神健康和精神病学

来源: Matrix Medical Communications, LLC

【 摘 要 】

Objective: To evaluate the efficacy of lisdexamfetamine dimesylate in adults with attention deficit hyperactivity disorder symptom subtypes who exhibit predominantly inattention, hyperactivity/ impulsivity, or combined symptom clusters.

【 授权许可】

Unknown